These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33234004)

  • 21. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
    Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic options to reduce LDL-cholesterol beyond statins].
    Weingärtner O; Marx N; Klose G; Laufs U
    Dtsch Med Wochenschr; 2022 Aug; 147(15):1001-1012. PubMed ID: 35915886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newer cholesterol-lowering agents: What you must know.
    Firnhaber JM
    J Fam Pract; 2018 Jun; 67(6):339;341;344;345. PubMed ID: 29879234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Eligibility for the indication of PCSK9 inhibitors according to the recommendations of different scientific societies].
    Siniawski D; Masson W; Rossi E; Damonte J; Halsband A; Pizarro R
    Medicina (B Aires); 2019; 79(2):104-110. PubMed ID: 31048275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    Lüscher TF
    Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
    Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
    Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
    Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
    Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab.
    Xu Q; Deng Y; Xiao J; Liu X; Zhou M; Ren Z; Peng J; Tang Y; Jiang Z; Tang Z; Liu L
    Curr Med Chem; 2021; 28(5):1025-1041. PubMed ID: 32368969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combined lipid-lowering therapy].
    Karásek D
    Vnitr Lek; 2019; 64(12):1177-1184. PubMed ID: 30704254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
    Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
    J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
    Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
    Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels.
    Groves C; Shetty C; Strange RC; Waldron J; Ramachandran S
    Postgrad Med J; 2017 Apr; 93(1098):205-208. PubMed ID: 27531965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.